Advanced Malignant Neoplasm Clinical Trial
Official title:
Double-Blinded, Placebo-Controlled Pilot Trial to Explore Whether Lipids Prevent Carboplatin and Oxaliplatin Hypersensitivity Reactions
This randomized pilot trial studies how well fat emulsion works in preventing hypersensitivity reactions in patients with cancer receiving carboplatin or oxaliplatin. Giving lipids before chemotherapy may prevent some drug reactions from carboplatin or oxaliplatin.
PRIMARY OBJECTIVES: I. To determine if the infusion of a lipid emulsion before each dose of chemotherapy appears to prevent carboplatin and oxaliplatin hypersensitivity reactions in high-risk patients. II. To explore if lipid infusions modulate a well-established panel of mediators of hypersensitivity reactions and if these mediators appear to predict reactions. OUTLINE: Patients are randomized to 1 of 2 groups. GROUP I: Patients receive fat emulsion intravenously (IV) immediately before each dose of either carboplatin or oxaliplatin. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity. GROUP II: Patients receive placebo IV immediately before each dose of either carboplatin or oxaliplatin. Treatment continues for up to 2 years in the absence of disease progression or unacceptable toxicity. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03671226 -
Preference of Room Setting and Waiting Time in Patients With Advanced, Locally Advanced, or Metastatic Cancer and Their Caregivers Who Are Seen in the Outpatient Supportive/Palliative Care Center
|
N/A | |
| Recruiting |
NCT05048160 -
A Clinical Study of 6MW3211 Injection in the Treatment of Advanced Malignant Neoplasm
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03287492 -
RCT of QPS vs General Information Sheet
|
N/A | |
| Recruiting |
NCT01549067 -
The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation Survey
|
N/A | |
| Recruiting |
NCT04119037 -
Cordotomy in Reducing Pain in Patients With Advanced Cancer
|
N/A | |
| Recruiting |
NCT04067336 -
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04585750 -
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
|
Phase 1/Phase 2 | |
| Completed |
NCT02823652 -
Pre-Test Genetic Education and Remote Genetic Counseling in Communicating Tumor Profiling Results to Patients With Advanced Cancer
|
N/A | |
| Completed |
NCT00244972 -
Tipifarnib and Sorafenib Tosylate in Treating Patients With Biopsiable Advanced Cancer
|
Phase 1 | |
| Recruiting |
NCT06297642 -
TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.
|
Phase 1 | |
| Active, not recruiting |
NCT01582191 -
Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT03856060 -
Videos and Questionnaires in Assessing Patient Perception of Physician's Compassion, Communication Skills, and Professionalism During Clinic Visits
|
N/A | |
| Completed |
NCT04186884 -
Caregiver Burden, Quality of Life, and Symptom Distress at Different Palliative Cancer Care Settings
|
||
| Completed |
NCT02583269 -
Muscadine Grape Skin Extract in Treating Patients With Malignancy That Is Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
| Withdrawn |
NCT03868423 -
Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers
|
Phase 2 | |
| Terminated |
NCT02940223 -
Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01552434 -
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
|
Phase 1 | |
| Active, not recruiting |
NCT03021486 -
Haloperidol With or Without Chlorpromazine in Treating Delirium in Patients With Advanced, Metastatic, or Recurrent Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT03203525 -
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
|
Phase 1 | |
| Completed |
NCT01624766 -
Everolimus and Anakinra or Denosumab in Treating Participants With Relapsed or Refractory Advanced Cancers
|
Phase 1 |